A new method to improve islet transplantation for type 1 diabetes
A novel immunomodulatory approach to overcome innate and adaptiveimmune barriers to islet transplantation
['FUNDING_R01'] · UNIVERSITY OF MISSOURI-COLUMBIA · NIH-10734033
This study is looking at a new way to help people with type 1 diabetes by improving islet transplants, making it easier for the body to accept the new islets without needing strong medications that can have side effects.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MISSOURI-COLUMBIA (nih funded) |
| Locations | 1 site (COLUMBIA, UNITED STATES) |
| Trial ID | NIH-10734033 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the success of islet transplantation, a procedure that can help manage type 1 diabetes. It aims to develop an innovative immunomodulatory approach to address the challenges of islet rejection and the adverse effects of immunosuppressive drugs. By infusing islets into the liver, the study seeks to minimize immediate inflammatory reactions that typically damage transplanted islets. The goal is to achieve long-term survival of the transplanted islets without the need for chronic immunosuppression, potentially improving outcomes for patients with type 1 diabetes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with type 1 diabetes who may benefit from islet transplantation.
Not a fit: Patients who do not have type 1 diabetes or those who are not candidates for islet transplantation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and sustainable treatments for individuals with type 1 diabetes, reducing the need for lifelong immunosuppression.
How similar studies have performed: Previous research has shown promise in immunomodulatory approaches for transplantation, suggesting potential for success in this novel application.
Where this research is happening
COLUMBIA, UNITED STATES
- UNIVERSITY OF MISSOURI-COLUMBIA — COLUMBIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SHIRWAN, HAVAL — UNIVERSITY OF MISSOURI-COLUMBIA
- Study coordinator: SHIRWAN, HAVAL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: autoimmune disorder, autoimmunity disease, Autoimmune Diseases